553 related articles for article (PubMed ID: 28748411)
1. The role of von Willebrand factor in thrombotic microangiopathy.
Noone DG; Riedl M; Licht C
Pediatr Nephrol; 2018 Aug; 33(8):1297-1307. PubMed ID: 28748411
[TBL] [Abstract][Full Text] [Related]
2. Von Willebrand factor regulates complement on endothelial cells.
Noone DG; Riedl M; Pluthero FG; Bowman ML; Liszewski MK; Lu L; Quan Y; Balgobin S; Schneppenheim R; Schneppenheim S; Budde U; James P; Atkinson JP; Palaniyar N; Kahr WH; Licht C
Kidney Int; 2016 Jul; 90(1):123-34. PubMed ID: 27236750
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes.
Peyvandi F; Rossio R; Ferrari B; Lotta LA; Pontiggia S; Ghiringhelli Borsa N; Pizzuti M; Donadelli R; Piras R; Cugno M; Noris M
J Thromb Haemost; 2016 Feb; 14(2):340-5. PubMed ID: 26613809
[TBL] [Abstract][Full Text] [Related]
4. Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis.
Bettoni S; Galbusera M; Gastoldi S; Donadelli R; Tentori C; Spartà G; Bresin E; Mele C; Alberti M; Tortajada A; Yebenes H; Remuzzi G; Noris M
J Immunol; 2017 Aug; 199(3):1021-1040. PubMed ID: 28652401
[TBL] [Abstract][Full Text] [Related]
5. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
Furlan M; Lämmle B
Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles.
Skerka C; Licht C; Mengel M; Uzonyi B; Strobel S; Zipfel PF; Józsi M
Mol Immunol; 2009 Sep; 46(14):2801-7. PubMed ID: 19640589
[TBL] [Abstract][Full Text] [Related]
8. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
9. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab.
Pecoraro C; Ferretti AV; Rurali E; Galbusera M; Noris M; Remuzzi G
Am J Kidney Dis; 2015 Dec; 66(6):1067-70. PubMed ID: 26409664
[TBL] [Abstract][Full Text] [Related]
11. Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade.
Bitzan M; Hammad RM; Bonnefoy A; Al Dhaheri WS; Vézina C; Rivard GÉ
Pediatr Nephrol; 2018 Aug; 33(8):1437-1442. PubMed ID: 29728803
[TBL] [Abstract][Full Text] [Related]
12. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.
Phillips EH; Westwood JP; Brocklebank V; Wong EK; Tellez JO; Marchbank KJ; McGuckin S; Gale DP; Connolly J; Goodship TH; Kavanagh D; Scully MA
J Thromb Haemost; 2016 Jan; 14(1):175-85. PubMed ID: 26559391
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
Polito MG; Kirsztajn GM
J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
[TBL] [Abstract][Full Text] [Related]
14. A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity.
Rossio R; Lotta LA; Pontiggia S; Borsa NG; Garagiola I; Ardissino G; Mikovic D; Cugno M; Peyvandi F
Haematologica; 2015 Mar; 100(3):e87-9. PubMed ID: 25381125
[No Abstract] [Full Text] [Related]
15. Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1.
May O; Merle NS; Grunenwald A; Gnemmi V; Leon J; Payet C; Robe-Rybkine T; Paule R; Delguste F; Satchell SC; Mathieson PW; Hazzan M; Boulanger E; Dimitrov JD; Fremeaux-Bacchi V; Frimat M; Roumenina LT
Front Immunol; 2018; 9():3008. PubMed ID: 30619356
[TBL] [Abstract][Full Text] [Related]
16. [From gene to disease; congenital thrombotic thrombocytopenic purpura due to mutations in the ADAMTS13 gene].
Schiphorst RH; van de Kar NC; van den Heuvel LP
Ned Tijdschr Geneeskd; 2003 Dec; 147(49):2422-4. PubMed ID: 14694551
[TBL] [Abstract][Full Text] [Related]
17. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification.
Shenkman B; Einav Y
Autoimmun Rev; 2014; 13(4-5):584-6. PubMed ID: 24418304
[TBL] [Abstract][Full Text] [Related]
18. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
Nephrology (Carlton); 2018 Jun; 23(6):507-517. PubMed ID: 29419916
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.
Lian EC
Semin Thromb Hemost; 2005 Dec; 31(6):625-32. PubMed ID: 16388413
[TBL] [Abstract][Full Text] [Related]
20. Does severe ADAMTS13 deficiency in thrombotic microangiopathy rule out complement-mediated atypical hemolytic uremic syndrome.
Arumugam V; Bhowmick R; Agarwal I; Arumadi M
Saudi J Kidney Dis Transpl; 2019; 30(3):701-705. PubMed ID: 31249236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
